| Intracellular Mechanistic Understanding of 2D MoS2 Nanosheets for Anti-Exocytosis-Enhanced Synergistic Cancer Therapy X Zhu, X Ji, N Kong, Y Chen, M Mahmoudi, X Xu, L Ding, W Tao, T Cai, ... ACS nano 12 (3), 2922-2938, 2018 | 215 | 2018 |
| Intracellular fate of nanoparticles with polydopamine surface engineering and a novel strategy for exocytosis-inhibiting, lysosome impairment-based cancer therapy L Ding, X Zhu, Y Wang, B Shi, X Ling, H Chen, W Nan, A Barrett, Z Guo, ... Nano letters 17 (11), 6790-6801, 2017 | 173 | 2017 |
| Protective effects of quercetin on UVB irradiation‑induced cytotoxicity through ROS clearance in keratinocyte cells X Zhu, N Li, Y Wang, L Ding, H Chen, Y Yu, X Shi Oncology Reports 37 (1), 209-218, 2017 | 100 | 2017 |
| Topical use of quercetin-loaded chitosan nanoparticles against ultraviolet B radiation W Nan, L Ding, H Chen, FU Khan, L Yu, X Sui, X Shi Frontiers in pharmacology 9, 826, 2018 | 80 | 2018 |
| Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth PloS one 16 (2), e0246803, 2021 | 61 | 2021 |
| Pulmonary biofilm-based chronic infections and inhaled treatment strategies L Ding, J Wang, S Cai, H Smyth, Z Cui International Journal of Pharmaceutics 604, 120768, 2021 | 35 | 2021 |
| A quality by design framework for capsule-based dry powder inhalers L Ding, AD Brunaugh, S Stegemann, SV Jermain, MJ Herpin, J Kalafat, ... Pharmaceutics 13 (8), 1213, 2021 | 21 | 2021 |
| Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth BioRxiv, 2020.09. 24.310490, 2020 | 19 | 2020 |
| Comprehensive insights into intracellular fate of WS2 nanosheets for enhanced photothermal therapeutic outcomes via exocytosis inhibition N Kong, L Ding, X Zeng, J Wang, W Li, S Shi, ST Gan, X Zhu, W Tao, X Ji Nanophotonics 8 (12), 2331-2346, 2019 | 16 | 2019 |
| Rapamycin and FK506 derivative TH2849 could ameliorate neurodegenerative diseases through autophagy with low immunosuppressive effect L Ding, WH Nan, XB Zhu, XM Li, LY Zhou, HJ Chen, L Yu, F Ullah Khan, ... CNS neuroscience & therapeutics 25 (4), 452-464, 2019 | 14 | 2019 |
| Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder AD Brunaugh, L Ding, T Wu, M Schneider, R Khalaf, HDC Smyth Journal of Pharmaceutical Sciences 111 (2), 403-416, 2022 | 13 | 2022 |
| Comparison of Hpmc inhalation-grade capsules and their effect on aerosol performance using budesonide and rifampicin DPI formulations L Ding, AD Brunaugh, R Thakkar, C Lee, QJ Zhao, J Kalafat, ... AAPS PharmSciTech 23 (1), 52, 2022 | 4 | 2022 |
| Targeted treatment for biofilm-based infections using PEGylated tobramycin L Ding, G Wang, J Wang, Y Peng, S Cai, SU Khan, Z Cui, X Zhang, C Wu, ... Journal of Controlled Release 372, 43-58, 2024 | 2 | 2024 |
| Emerging Process Modeling Capabilities for Dry Powder Operations for Inhaled Formulations H Lou, L Ding, T Wu, W Li, R Khalaf, HDC Smyth, DL Reid Molecular Pharmaceutics 20 (11), 5332-5344, 2023 | 1 | 2023 |
| Intracellular mechanistic insights into cRGD-modified Bi2Se3 nanofoams for enhanced photothermal therapy via exocytosis inhibition L Ding, X Yu, S Cai, A Mahmood, W Meng, X Liu, J Liu, J Li, X Zhang, ... International Journal of Pharmaceutics 669, 125093, 2025 | | 2025 |
Xianbing ZhuMcGill UniversityVerified email at mail.mcgill.ca